Explore the vast range of titles available.

About the Book: Smoking is injurious to health. It has been estimated that about 1.3 billion are addicted to smoking and unless steps are taken to make people aware of the growing menace, 650 million people are likely to die prematurely due to the extensive use of tobacco. The book, Tobacco Use: Health and Behaviour, in twelve chapters, deals with a wide range of issues concerning its cultivation and its impact on the health of its users. It provides a critical test for our concepts of reality; discusses how it has assumed political, economic and medical importance since its introduction; magnitude of its use and its global trend; how the sophisticated, wealthy and powerful drug cartel, based on the western world, is dictating its availability in the developing countries; its effect and its addiction potential; and the treatment of tobacco cessation. It is a valuable book to understand the use of tobacco, and plan strategies to curb the growing menace. It is meant for students and practitioners of public health, community and preventive medicine, psychiatry, psychology and those involved in the study and planning in the field of addiction, particularly tobacco addiction. Contents: Introduction History of Tobacco Use: New World`s Revenge Global Trends in Tobacco Use Tobacco: Cultivation, Curing and Commerce Nicotine: Pharmacokinetics, Metabolism and Pharmacodynamics Addiction Model: Tobacco Use as Drug Dependence People at Risk: Initiation and Maintenance of Tobacco Use Women and Children: Victims of Passive Smoking Tobacco Use and Medical Morbidity Tobacco Use in Psychiatric Patients Smoking-Cessation and Treatment of Tobacco Dependence Tobacco Control in India Tobacco Use: 2020 and Beyond Index.

This convenient reference provides clinicians with point-of-care guidance to help their patients stop using tobacco- and nicotine-containing products--as well as the latest clinical data to encourage them to never start.

Smoking tobacco presents serious social problems with major impacts on public health. It is estimated that 25-30% of the general population in western countries are currently smoking. Tobacco use is the major preventable cause of death in the United States, responsible for more than 400,000 deaths annually. Within the USA and Europe, 70% of all smokers have tried to quit smoking at least once, but only about 6% of these succeeded in maintaining abstinence. This book covers the latest nicotine-related research. The selection of chapters has a certain unity as physiologic, pathologic and psychological themes run through the book and supply the logical connections between the various authors. This work is intended as a contribution to the reversal of the current tobacco epidemic and thereby to preventing many of the deaths attributable to tobacco predicted in this century.

This convenient reference provides clinicians with point-of-care guidance to help their patients stop using tobacco- and nicotine-containing products--as well as the latest clinical data to encourage them to never start.CONTENTS CONSIST OF Nicotine-Containing Products Tobacco Use Disorder/Adverse Effects Prevention and Treatment Withdrawal Management, With and Without Medication Policy and Resources.

¿Fumar?, ¿por qué?, ¿para qué? ¡Miles de personas fallecen cada año por su adicción al tabaco! ¡Recupere el placer de no fumar! Abandonar la adicción es el objetivo a conseguir, debido a que esto lleva implícito la recuperación de la salud, además de otra.

Addiction poses a major global public health challenge. It is characterized by high prevalence, chronic relapse and limited efficacy of available pharmacotherapies across different substance use disorders. Increasing evidence demonstrates that incretin-based therapies directly modulate metabolic signaling pathways that intercross with central reward and motivational circuits, including hypothalamic-mesolimbic networks and dopaminergic neurotransmission. As a result, agents such as glucagon-like peptide 1 receptor agonists, originally developed for the treatment of type 2 diabetes and obesity, are now being actively investigated for their role in addiction treatment. This narrative review summarizes the current knowledge on the role of incretin-based therapies in the neurobiology of addiction. Evidence from preclinical models and human studies supports the potential therapeutic effect of glucagon-like peptide 1 receptor agonists in the treatment of alcohol use disorder, nicotine dependence, and the administration of other psychoactive substances, including psychostimulants, opioids, and cannabinoids. Preclinical studies consistently demonstrate that glucagon-like peptide 1 receptor agonists reduce substance intake, attenuate reward-related behaviors, and suppress relapse-like responding. So far, human evidence remains limited and is largely derived from observational studies. Preliminary research suggests potential reductions in substance use severity and overdose risk among individuals treated with incretin-based agents. While these findings highlight incretin signaling as a promising therapeutic option in addiction, the current evidence is insufficient to support their routine clinical use in the treatment of substance dependence. Therefore, further research is required to clarify underlying mechanisms and establish clinical efficacy. In particular, well-designed randomized controlled trials are needed to determine safety, tolerance and effectiveness of incretin-based therapies across different substance use disorders.

Background Substance use disorders (SUDs) are prevalent in the general population, tend to follow a chronic course, are associated with many individual and social problems, and often have their onset in adolescence. However, the knowledge base from prospective population surveys and treatment-outcome studies on the course of SUD in adolescents is limited at best. The present study aims to fill this gap and focuses on a subgroup that is particularly at risk for chronicity: adolescents in addiction treatment. We will investigate the rate of persistent SUD and its predictors longitudinally from adolescence to young adulthood among youth with DSM-5 SUD from the start of their addiction treatment to 2 and 4 years following treatment-entry. In addition to SUD, we will investigate the course of comorbid mental disorders, social functioning, and quality of life and their association with SUD over time. Methods/design In a naturalistic, multi-center prospective cohort design, we will include youths ( n  = 420), who consecutively enter addiction treatment at ten participating organizations in the Netherlands. Inclusion is prestratified by treatment organization, to ensure a nationally representative sample. Eligible youths are 16 to 22 years old and seek help for a primary DSM-5 cannabis, alcohol, cocaine or amphetamine use disorder. Assessments focus on lifetime and current substance use and SUD, non-SUD mental disorders, family history, life events, social functioning, treatment history, quality of life, chronic stress indicators (hair cortisol) and neuropsychological tests (computerized executive function tasks) and are conducted at baseline, end of treatment, and 2 and 4 years post-baseline. Baseline data and treatment data (type, intensity, duration) will be used to predict outcome – persistence of or desistance from SUD. Discussion There are remarkably few prospective studies worldwide that investigated the course of SUD in adolescents in addiction treatment for longer than 1 year. We are confident that the Youth in Transition study will further our understanding of determinants and consequences of persistent SUD among high-risk adolescents during the critical transition from adolescence to young adulthood. Trial registration The Netherlands National Trial Register Trial NL7928 . Date of registration January 17, 2019.